Stockreport

Prelude Therapeutics Announces Third Quarter 2020 Financial Results

Prelude Therapeutics Incorporated  (PRLD) 
PDF - Completed Initial Public Offering of Common Stock, Raising Gross Proceeds of ~$181.9M - - Partial Response Confirmed in Glioblastoma Multiforme Patient in Phase 1 T [Read more]